Drugs Made In America Acquisition II Corp. ( (DMII) ) has released a notification of late filing.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Drugs Made in America Acquisition II Corp. has filed a Form 12b-25 to notify investors of a delay in submitting its Form 10-K (Yearly Report) for the fiscal year ended December 31, 2025. The company is seeking short-term relief from the normal deadline for its annual SEC filing and confirms this delay only affects its Form 10-K (Yearly Report).
The company cites difficulty compiling all required financial statements and related disclosures in time, stating that timely completion would have required unreasonable effort or expense. No issues such as auditor changes, restatements, or identified control failures are mentioned, suggesting the delay is largely logistical and related to closing and reporting processes.
Management has indicated that the Form 10-K (Yearly Report) is expected to be filed on or before April 15, 2026, which falls within the 15-day extension allowed under SEC rules for annual reports. Investors should treat this as a relatively standard timing extension rather than an open-ended delay, assuming the company meets this stated target.
The company does not anticipate any significant change in results of operations versus the prior fiscal year to be reflected in the upcoming annual report. No preliminary financial data or revisions to prior results are disclosed at this time, and any forward-looking expectations remain subject to change once the final Form 10-K (Yearly Report) is filed and reviewed by investors.
Drugs Made in America Acquisition II Corp. affirms that all other required periodic reports over the past 12 months have been filed, underscoring its intention to remain in compliance with SEC reporting rules. The notification is signed by Chief Executive Officer Roger E. Bendelac on April 1, 2026, signaling senior management’s responsibility for the delayed filing and the company’s commitment to complete the annual report promptly.
More about Drugs Made In America Acquisition II Corp.
Drugs Made in America Acquisition II Corp. is a special purpose acquisition company (SPAC) formed to identify and merge with one or more businesses, with a thematic focus on the U.S. pharmaceuticals and healthcare sector. The company is listed in the United States and files periodic reports with the Securities and Exchange Commission as a public reporting entity.
Average Trading Volume: 114,632
Current Market Cap: $653.8M
Learn more about DMII stock on TipRanks’ Stock Analysis page.